Stroma Medical

Executive Summary

Stroma Medical is a clinical-stage medical device company pioneering a non-invasive laser procedure to permanently change eye color. Its patented Strōma Laser System targets the iris's melanin pigment, enabling patients with brown, hazel, or black eyes to achieve lighter colors such as blue, green, or grey. The treatment is designed as a quick, in-office procedure requiring only topical anesthetic, positioning it as a cosmetic alternative to colored contact lenses or surgical implants. Despite the aesthetic focus, the technology holds potential for therapeutic applications, such as treating iris hyperpigmentation or congenital heterochromia. The company is currently in Phase 1 clinical development, having demonstrated early safety and feasibility in preclinical studies. The procedure's unique value proposition lies in its permanence and non-invasive nature, potentially capturing a large elective market. However, regulatory hurdles (FDA Class II/III device pathway) and safety concerns—such as uveitis, glaucoma, or intraocular inflammation—remain key risks. Stroma Medical's success hinges on rigorous clinical validation to address these risks and gain regulatory approval. The company has not disclosed public funding or partnerships, suggesting it may be bootstrapped or seeking strategic investors. With no direct competitors in the permanent eye color change space, Stroma Medical occupies a niche but high-visibility segment. Commercialization would require strong physician training and consumer marketing to drive adoption. Given the early stage, conviction is moderate pending pivotal data.

Upcoming Catalysts (preview)

• Q1 2027Completion of Phase 1 safety study60% success
• Q3 2026FDA breakthrough device designation or pre-submission meeting40% success
• H2 2026Partnership or licensing deal with ophthalmic device company25% success